Takhzyro (lanadelumab-flyo) is a monoclonal antibody that works by reducing the activity of an enzyme that is uncontrolled in people with hereditary angioedema (a rare genetic immune system disorder).
Takhzyro is used to prevent attacks of hereditary angioedema (HAE) in people who are at least 12 years old.
